U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948318) titled 'A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia' on April 25.
Brief Summary: Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed. The main aim of this study is to check how safe mezagitamab is and how well it is tolerated by adults with chronic primary ITP, if given over a longer time. Other aims are to learn how effective treatment with mezagitamab is and how the body processes it (called pharmacokinetics or PK) ove...